
<!DOCTYPE html>
<html>
<head>
<title>12_1_MASTER_ALEXION_P03_T05_S02</title>
<meta name="viewport" content="user-scalable=no, width=device-width, initial-scale=1.0, maximum-scale=1.0"/>
<meta name="apple-mobile-web-app-capable" content="yes" />
<meta name="format-detection" content="telephone=no" />


<link href="../global/css/font.css" type="text/css" rel="stylesheet">
<link href="../global/css/global.css" type="text/css" rel="stylesheet">
<link href="css/main.css" type="text/css" rel="stylesheet">
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
</head>
<body>
<div id="container">
<div class="logo"></div>
<!--end elements-->
<div id="main_container" class="bg_blue">
  <div class="btn_reload"></div>
  <div class="claim"> The balanced approach that helps<br>
    improve upper-GI<sup>§</sup> tolerability.<sup>†</sup> </div>
  <div class="title_left brown Helvetica_Round_Bold">
    <i18n id="v2_txt1">VIMOVO helps more<br>
      patients remain on therapy<br>
      vs EC naproxen.<sup>1</sup></i18n>
  </div>
  <div class="percent Helvetica_Round_Bold brown">
    <i18n id="v2_txt2">67%</i18n>
  </div>
  <div class="percent_txt HelveticaLTStd_Roman">
    <i18n id="v2_txt3"><span class="Helvetica_Round_Bold grey">fewer discontinuations</span><br>
      <br>
      Relative risk reduction (RRR) due 
      to predefined, NSAID-related,<br />
      upper-GI issues (including 
      duodenal ulcers) vs EC naproxen 
      monotherapy<sup>1,2</sup>  (results are based 
      on a pooled analysis).</i18n>
  </div>
  <div class="title_chart HelveticaLTStd_Roman">
    <i18n id="v2_txt4"> % of Patients (≤ 50 or with a history of peptic ulceration)<br>
      discontinuing therapy due to upper-GI issues. OA, RA, AS, and other<br>
      patients requiring daily NSAID. Pooled analysis, Studies 301 and 302.</i18n>
  </div>
</div>

<div class="chart">
  
  <div class="bar" id="bar1">
  <div class="grey_chart Helvetica_Round_Bold">
    <i18n id="v2_txt5">12.0%</i18n>
  </div>
    <div class="wrapper"></div>
    <div class="blue_chart Helvetica_Round_Bold">
	  	
      <i18n id="v2_txt6" class='blue_percent'></i18n>
    </div>
  </div>
  <div class="shadow"></div>
  <div class="number_chart">
    <ul>
      <li>
        <i18n id="v2_txt7"><span class="blue Helvetica_Round_Bold">VIMOVO</span><br>
          <span class="Helvetica_Round_Bold">EC naproxen</span></i18n>
      </li>
    </ul>
  </div>
  <div class="right_colum">
    <ul>
      <li>
        <i18n id="txt8">p < 0.001 VIMOVO vs EC naproxen</i18n>
      </li>
    </ul>
  </div>
</div>

<div class="btn_ok"></div>
<!--End #main_container -->
        <div class="ref_wrapper" id="ref_all"></div>	
        <div id="scroll-wrapper" class="scroll_ref">
			<div id="scroller">	
                <h1 class="brown Helvetica_Round_Bold"><i18n id="v2_v1_S007_ref">References:</i18n></h1>
                
				<div class="ref HelveticaLTStd_Roman">
               		<span class="ref_number">1.</span>
                	<i18n id="v2_v1_S007_ref_txt0">Adapted from Goldstein, JL, et al. <span class="HelveticaNeueLTStd_it">Aliment Pharmacol Ther</span> 2010; 32: 401-413.</i18n>
                </div>	
				
                 <div class="ref HelveticaLTStd_Roman">
               		<span class="ref_number">2.</span>
                	<i18n id="v2_v1_S007_ref_txt1">Predefined upper-GI adverse events include: abdominal 
discomfort, abdominal pain, abdominal tenderness, duodenal 
hemorrhage, duodenal scarring, DU hemorrhage, duodenitis, 
dyspepsia, epigastric discomfort, erosive esophagitis, erosive 
gastritis, esophageal discomfort, esophageal disorder, esophageal hemorrhage, esophageal stenosis, esophageal ulcer, esophageal varices, esophagitis, gastric hemorrhage, gastric mucosal lesion, gastritis, GERD, gastro-esophagitis, GI erosion, GI hemorrhage, 
GI mucosal disorder, hemorrhagic duodenitis, hemorrhagic 
gastritis, hyperchloridia, nausea, reflux esophagitis, stomach 
discomfort, upper abdominal pain, vomiting (NSAID, nonsteroidal anti-inflammatory drug; AE, adverse event; DU, duodenal ulcer; GERD, gastro-esophageal reflux disease).</i18n>
                </div>
                
                <div class="ref HelveticaLTStd_Roman">
					<span class="ref_number">§</span>
                    <i18n id="v2_v1_S007_ref_txt5">Gastrointestinal</i18n>
				</div>  <!--end Ref-->           
               
                
                <div class="ref HelveticaLTStd_Roman">
					<span class="ref_number">†</span>
                    <i18n id="v2_v1_S007_ref_txt7">
					Helping to improve upper-GI tolerability is evidenced by fewer upper-GI ulcers, fewer discontinuations due to upper-GI AEs including duodenal ulcers, and less abdominal discomfort over 
a 6-month period as measured by dyspepsia symptoms versus 
EC naproxen.
                    </i18n>
				</div>				
			</div>
            <div class="close"><span class="right"></span></div>
            <div class="arrow_ref"></div>
		</div>
            		
		<!--End area for ref-->
        
        <div class="info_wrapper" id="info_all"></div>
		<div id="scroll-wrapper" class="scroll_info">
			<div id="scroller">	
                <h1 class="brown Helvetica_Round_Bold"><i18n id="v2_v1_S007_ref">Study design:</i18n></h1>
                
				<div class="ref HelveticaLTStd_Roman ref_1">					
                    <i18n id="info1">Study 301 was a 6-month randomized, double-blind, multi-center study in patients (stratified by low-dose aspirin ≤ 325mg use) with OA, RA or AS, or chronic musculoskeletal conditions requiring ongoing NSAID therapy, at risk of GI toxicity from daily NSAID use. Patients aged ≥ 50 years or 18-49 years with a history of ulcer were randomized to either VIMOVO 500/20mg or EC naproxen 500mg twice daily. The primary endpoint was cumulative incidence of endoscopic gastric ulcers, over 6 months. Study 302 was of 
similar design.¹
</i18n>
				</div>		
			</div>
            <div class="close"><span class="right"></span></div>
			<div class="arrow_info"></div>
		</div>

</div>
</body>
	<script type="text/javascript" src="../global/js/config.js"></script>
    <script type='text/javascript' src='../framework/steal/steal.production.js?../framework,development'></script>
	
	<script src="resource:js/SystemBridge.js"></script>
	<script type="text/javascript" src="../global/js/havie.js"></script>
    <script type="text/javascript" src="../global/js/global.js"></script>
    <script type="text/javascript" src="../global/js/ref.js"></script>
    <script type="text/javascript" src="javascript/main.js"></script>	
</html>
   